MedTrace Logo

Vaginal Estrogen for Asymptomatic Microscopic Hematuria

NCT03033160 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-10-12

No results posted yet for this study

Summary

The specific aim of this protocol is to determine whether vaginal estrogen is an effective treatment for asymptomatic microscopic hematuria in postmenopausal women. The investigators hypothesize that women who use vaginal estrogen for three months will be more likely to have resolution of their asymptomatic microscopic hematuria compared with women who do not use vaginal estrogen.

Conditions

  • Asymptomatic Microscopic Hematuria

Interventions

DRUG

Estradiol Ring

Sponsors & Collaborators

Principal Investigators

  • Lekha Hota, MD · Practitioner

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-10-31
Completion
2020-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033160 on ClinicalTrials.gov